Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in Ex Vivo and In Vivo Models of Autosomal Dominant Polycystic Kidney Disease

Peri-renal adipose inflammation contributes to renal dysfunction in a non-obese prediabetic rat model: Role of anti-diabetic drugs

(2021) Safaa H. Hammoud et al.   BIOCHEMICAL PHARMACOLOGY

Principles of Kidney Pharmacotherapy for the Nephrologist: Core Curriculum 2021

(2021) Sheryl F. Vondracek et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Revisit ligand-receptor interaction at the human vasopressin V2 receptor: A kinetic perspective

(2020) Chunji Liu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Autosomal dominant polycystic kidney disease

(2019) Emilie Cornec-Le Gall et al.   LANCET

Long residence time adenosine A1 receptor agonists produce sustained wash-resistant antilipolytic effect in rat adipocytes

(2019) Yi Yun et al.   BIOCHEMICAL PHARMACOLOGY

Pharmacokinetic–pharmacodynamic models that incorporate drug–target binding kinetics

(2019) Fereidoon Daryaee et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Interactions between Macrophages and Cyst-Lining Epithelial Cells Promote Kidney Cyst Growth inPkd1-Deficient Mice

(2018) Yang Yang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

OUP accepted manuscript

(2018)   NEPHROLOGY DIALYSIS TRANSPLANTATION

OUP accepted manuscript

(2018)   NEPHROLOGY DIALYSIS TRANSPLANTATION

Ganoderma triterpenes retard renal cyst development by downregulating Ras/MAPK signaling and promoting cell differentiation

(2017) Limin Su et al.   KIDNEY INTERNATIONAL

A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy

(2017) Fereidoon Daryaee et al.   Chemical Science

The Target Residence Time of Antihistamines Determines Their Antagonism of the G Protein-Coupled Histamine H1 Receptor

(2017) Reggie Bosma et al.   Frontiers in Pharmacology

Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Receptor: The Case of the Adenosine Receptors

(2016) Dong Guo et al.   CHEMICAL REVIEWS

Phase II and phase III failures: 2013–2015

(2016) Richard K. Harrison   NATURE REVIEWS DRUG DISCOVERY

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

(2016) Ron T. Gansevoort et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

The Role of Binding Kinetics in GPCR Drug Discovery

(2015) David Swinney et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models

(2015) Elayne Chan-Penebre et al.   Nature Chemical Biology

The drug–target residence time model: a 10-year retrospective

(2015) Robert A. Copeland   NATURE REVIEWS DRUG DISCOVERY

Drug-Target Residence Time-A Case for G Protein-Coupled Receptors

(2014) Dong Guo et al.   MEDICINAL RESEARCH REVIEWS

Pharmacokinetics and the drug–target residence time concept

(2013) Göran Dahl et al.   DRUG DISCOVERY TODAY

Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time

(2012) Dong Guo et al.   BRITISH JOURNAL OF PHARMACOLOGY

Rebinding: or why drugs may act longerin vivothan expected from theirin vitrotarget residence time

(2010) Georges Vauquelin   Expert Opinion on Drug Discovery

Exploring the Mechanism of Agonist Efficacy: A Relationship between Efficacy and Agonist Dissociation Rate at the Muscarinic M3 Receptor

(2009) D. A. Sykes et al.   MOLECULAR PHARMACOLOGY

Small-Molecule CFTR Inhibitors Slow Cyst Growth in Polycystic Kidney Disease

(2008) B. Yang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY